Английская Википедия:GSBR-1290

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Orphan Шаблон:Infobox drug

GSBR-1290 is a small-molecule GLP-1 agonist developed by Structure Therapeutics.[1] It is delivered orally and is in a Phase II trial as of 2023.[2][3][4] On 18 December 2023 trial results failed to meet exceptions and Structure Therapeutics share price lost half its value.[5]

References

Шаблон:Reflist